Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gene engineering monoclonal antibody combined with A-beta oligomer specificity

A monoclonal antibody and oligomer technology, applied in the direction of antibodies, drug combinations, microorganism-based methods, etc., can solve the problem that the spatial three-dimensional antigen epitope has not been clearly explored, and achieve strong activity, easy screening, and reduced toxicity. Effect

Inactive Publication Date: 2013-02-27
TSINGHUA UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] The present invention solves the technical problem that existing antibodies bind to A-beta monomers, oligomers and filaments at the same time, and uses phage display technology to successfully screen out antibodies that specifically bind to A-beta oligomers but do not bind to A-beta oligomers. beta monomer and filament-bound monoclonal antibody
Its three-dimensional epitope has not been explored clearly so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene engineering monoclonal antibody combined with A-beta oligomer specificity
  • Gene engineering monoclonal antibody combined with A-beta oligomer specificity
  • Gene engineering monoclonal antibody combined with A-beta oligomer specificity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1A-be

[0049] Example 1A-Preparation of beta oligomers

[0050] A-beta monomer (purchased from American Peptide, USA) was dissolved in HFIP (hexafluoroisopropanol, purchased from Sigma) to prepare a solution with a concentration of 1 mg / ml. Ultrasonic treatment in a water bath at room temperature for 10 minutes, aliquoted into 1.5ml centrifuge tubes, placed in a fume hood to allow HFIP to completely evaporate, and stored at -20°C for later use.

[0051] After the above-treated A-beta was equilibrated at room temperature for 10 minutes, DMSO (dimethyl sulfoxide, purchased from Sigma) was added to fully dissolve A-beta, and the final concentration was 1 mg / ml. A certain amount of A-beta was added to pH 7.4 PBS buffer to make A-beta concentration 10 μM. The A-beta solution was incubated at 37° C. for 12 hours, centrifuged at 14,000 rpm for 20 minutes, and the bottom precipitate was discarded to obtain the A-beta oligomer-containing supernatant. The formation of A-beta oligomers in the...

Embodiment 2

[0052] Example 2 Screening of positive clones

[0053] The A-beta oligomer obtained in Example 1 was diluted to 10-100 μg / mL with coating buffer (PBS, pH=7.4), 4 mL was added to the immunotube, and coated overnight at 4°C. The supernatant was discarded and the tube was quickly washed 3 times with PBS. The immunotubes were filled with 3% BSA and blocked vertically for 2 h at room temperature. The supernatant was discarded and the tube was quickly washed 3 times with PBS. The phage antibody library (purchased from MRC Centre, UK) was suspended in 4 mL of 3% BSA and added to the immunotube, incubated upside down for 1 h at room temperature, and then incubated vertically for 1 h. 10 washes with 0.1% Tween-20 in PBS (20 washes for the second round of screening and beyond). After the PBS was blotted dry, 500 μL of trypsin-PBS solution was added to elute the phage, and the cells were incubated upside down for 10 min at room temperature. 250 μL of the eluted phage was added to 1.7...

Embodiment 3

[0060] Example 3 Identification of Antibodies

[0061] Abeta monomers, oligomers and fibrils (Abeta monomers were incubated at 37°C for more than 4 days and verified by atomic force microscopy) were spotted onto 3 μL of NC (nitrocellulose) membranes respectively. After blocking the membrane with 5% BSA, scFv W9 was added to incubate for 1 hour, and the membrane was washed three times with PBS for 5 minutes each. Then, 1:5000 diluted Protein A (purchased from Santa Cruz, USA) was added to incubate for 1 hour, and the membrane was washed three times with PBST (Tween-20 concentration of 0.1%) for 5 minutes each time, and color was developed with DAB. Only clones showing spots at A-beta oligomers, not A-beta monomers and fibrils were the desired clones.

[0062] The above positive clones are sequenced and identified, and the clones that conform to the basic structure of the antibody in the antibody library are complete single-chain genetically engineered antibodies. The sequenci...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of engineered antibody and provides a monoclonal antibody. The variable region of heavy chain of the monoclonal antibody contains the amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEO ID NO.3; the variable region of light chain of the monoclonal antibody contains the amino acid sequences shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The invention also specifically provides a humanization single-chain antibody generated by the recombinant strain of enterotoxigenic Escherichia coli with the accession number CGMCC No.2820 and the amino acid sequence of the humanization single-chain antibody is shown in SEQ ID NO.7. The antibody of the invention can be specifically bound with A-beta oligomer, effectively inhibit the fibrosis aggregation of A-beta and obviously alleviate the toxic effect of the A-beta on cells. The invention also relates to a pharmaceutical composite containing the antibody. The antibody of the invention has strong activity, good specificity, easy preparation and wide prospect of experiment application and clinical application.

Description

technical field [0001] The present invention belongs to the technical field of genetically engineered antibodies, in particular to a genetically engineered monoclonal antibody that specifically binds to A-beta oligomers. The present invention also relates to a preparation method of the monoclonal antibody and a pharmaceutical composition containing the monoclonal antibody. Background technique [0002] Studies have shown that Alzheimer's Disease (AD), commonly known as senile dementia, is caused by non-toxic β-amyloid monomer molecules (β-Amyloid, A-beta 40 / 42 hereinafter referred to as A-beta, also known as β-amyloid). A neurodegenerative disease in the elderly mainly characterized by memory loss and the formation of senile plaques in the brain (Selkoe et al., Science 1997, 275, 630-631; Koo et al., PNAS 1996, 9989-9990). Medical statistics show that 5-6% of the elderly over the age of 60 in my country and European and American countries suffer from Alzheimer's disease. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/18C12N1/21G01N33/577A61K39/395A61P25/28C12R1/19
Inventor 刘瑞田王小平
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com